chrisvoncsefalvay/vaers-narrative-generation huggingface dataset:
Age: 41.0
Sex: F
Vaccine: COVID19, COVID19, COVID19, COVID19
Symptoms: Anxiety, Bell's palsy, Blood pressure increased, Blood test, Hypoaesthesia
Clinical narrative: Mild anaphylactic throat swelling at clinic; Mild anaphylactic throat swelling at clinic; left side head nerve inflammation; ear muffled- no infection; head twitching/spasm, dull, burning, sharp, neddle; head twitching/spasm, dull, burning, sharp, neddle; head twitching/spasm, dull, burning, sharp, neddle/head pressure; head twitching/spasm, dull, burning, sharp, neddle/head pressure; head twitching/spasm, dull, burning, sharp, neddle; migraine line pains; sinus pressure; tinnitus; heightened anxiety; nerve zaps in brain, toes and tooth; dizziness; bdain fog; speech problem; mini stroke like symptoms; insomnia; base skull feels swollen; High inflammation markers; This is a spontaneous report from a contactable consumer (patient). This 41-year-old female patient received bnt162b2 (Brand: Pfizer), dose 2 via an unspecified route of administration, administered in arm right on 23Mar2021 (Batch/Lot Number: ER781) as dose 2, single at the age of 41-year-old for covid-19 immunisation. Medical history included high bp and known allergies penicillin. Concomitant medications included hydroxyzine hydrochloride (HYDROXIZINE) taken for an unspecified indication, start and stop date were not reported; hydrochlorothiazide, losartan potassium (LOSARTAN HCTZ) taken for an unspecified indication, start and stop date were not reported. No other vaccine in four weeks. Facility where the most recent COVID-19 vaccine was administered: Other. First dose was received on 23Mar2021 08:30 am in arm left at the age of 41-year-old with Batch/lot number: EN6208 and experienced all Left side - Face numbness, mild inner mouth swelling, ER visit, went away after 2 weeks, and very heavy legs. Adverse event 2nd dose: mild anaphylactic throat swelling at clinic, doubled on hydroxyzine per nurse. 10 days post (as reported): left side head nerve inflammation, ear muffled- no infection, head twitching/spasm, dull, burning, sharp needle, migraine line pains, sinus pressure, head pressure, tinnitus, heightened anxiety, nerve zaps in brain, toes and tooth, dizziness, brain fog, speech problem, mini stroke like symptoms, insomnia, base skull feels swollen. ER, primary doc, neurons and physical therapists being seen. No treatments avail...VAX reaction confirmed. High inflammation markers. Adverse event start date reported as 06May2021 08:00 am. Events resulted in Doctor or other healthcare professional office/clinic visit, Emergency room/department or urgent care, Life threatening illness (immediate risk of death from the event), Disability or permanent damage. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient has been tested for COVID-19. Covid test post vaccination covid test type post vaccination: Nasal Swab on 11Jul2021: Negative. Treatment was unknown. The patient was not recovered.
Age: 41.0
Sex: F
Vaccine: COVID19, COVID19, COVID19, COVID19
Symptoms: Mouth swelling
Clinical narrative: Mild anaphylactic throat swelling at clinic; Mild anaphylactic throat swelling at clinic; left side head nerve inflammation; ear muffled- no infection; head twitching/spasm, dull, burning, sharp, neddle; head twitching/spasm, dull, burning, sharp, neddle; head twitching/spasm, dull, burning, sharp, neddle/head pressure; head twitching/spasm, dull, burning, sharp, neddle/head pressure; head twitching/spasm, dull, burning, sharp, neddle; migraine line pains; sinus pressure; tinnitus; heightened anxiety; nerve zaps in brain, toes and tooth; dizziness; bdain fog; speech problem; mini stroke like symptoms; insomnia; base skull feels swollen; High inflammation markers; This is a spontaneous report from a contactable consumer (patient). This 41-year-old female patient received bnt162b2 (Brand: Pfizer), dose 2 via an unspecified route of administration, administered in arm right on 23Mar2021 (Batch/Lot Number: ER781) as dose 2, single at the age of 41-year-old for covid-19 immunisation. Medical history included high bp and known allergies penicillin. Concomitant medications included hydroxyzine hydrochloride (HYDROXIZINE) taken for an unspecified indication, start and stop date were not reported; hydrochlorothiazide, losartan potassium (LOSARTAN HCTZ) taken for an unspecified indication, start and stop date were not reported. No other vaccine in four weeks. Facility where the most recent COVID-19 vaccine was administered: Other. First dose was received on 23Mar2021 08:30 am in arm left at the age of 41-year-old with Batch/lot number: EN6208 and experienced all Left side - Face numbness, mild inner mouth swelling, ER visit, went away after 2 weeks, and very heavy legs. Adverse event 2nd dose: mild anaphylactic throat swelling at clinic, doubled on hydroxyzine per nurse. 10 days post (as reported): left side head nerve inflammation, ear muffled- no infection, head twitching/spasm, dull, burning, sharp needle, migraine line pains, sinus pressure, head pressure, tinnitus, heightened anxiety, nerve zaps in brain, toes and tooth, dizziness, brain fog, speech problem, mini stroke like symptoms, insomnia, base skull feels swollen. ER, primary doc, neurons and physical therapists being seen. No treatments avail...VAX reaction confirmed. High inflammation markers. Adverse event start date reported as 06May2021 08:00 am. Events resulted in Doctor or other healthcare professional office/clinic visit, Emergency room/department or urgent care, Life threatening illness (immediate risk of death from the event), Disability or permanent damage. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient has been tested for COVID-19. Covid test post vaccination covid test type post vaccination: Nasal Swab on 11Jul2021: Negative. Treatment was unknown. The patient was not recovered.
Age: 41.0
Sex: F
Vaccine: COVID19, COVID19, COVID19, COVID19
Symptoms: Hypoaesthesia, Inappropriate schedule of product administration, Limb discomfort, Mouth swelling, SARS-CoV-2 test
Clinical narrative: Mild anaphylactic throat swelling at clinic; Mild anaphylactic throat swelling at clinic; left side head nerve inflammation; ear muffled- no infection; head twitching/spasm, dull, burning, sharp, neddle; head twitching/spasm, dull, burning, sharp, neddle; head twitching/spasm, dull, burning, sharp, neddle/head pressure; head twitching/spasm, dull, burning, sharp, neddle/head pressure; head twitching/spasm, dull, burning, sharp, neddle; migraine line pains; sinus pressure; tinnitus; heightened anxiety; nerve zaps in brain, toes and tooth; dizziness; bdain fog; speech problem; mini stroke like symptoms; insomnia; base skull feels swollen; High inflammation markers; This is a spontaneous report from a contactable consumer (patient). This 41-year-old female patient received bnt162b2 (Brand: Pfizer), dose 2 via an unspecified route of administration, administered in arm right on 23Mar2021 (Batch/Lot Number: ER781) as dose 2, single at the age of 41-year-old for covid-19 immunisation. Medical history included high bp and known allergies penicillin. Concomitant medications included hydroxyzine hydrochloride (HYDROXIZINE) taken for an unspecified indication, start and stop date were not reported; hydrochlorothiazide, losartan potassium (LOSARTAN HCTZ) taken for an unspecified indication, start and stop date were not reported. No other vaccine in four weeks. Facility where the most recent COVID-19 vaccine was administered: Other. First dose was received on 23Mar2021 08:30 am in arm left at the age of 41-year-old with Batch/lot number: EN6208 and experienced all Left side - Face numbness, mild inner mouth swelling, ER visit, went away after 2 weeks, and very heavy legs. Adverse event 2nd dose: mild anaphylactic throat swelling at clinic, doubled on hydroxyzine per nurse. 10 days post (as reported): left side head nerve inflammation, ear muffled- no infection, head twitching/spasm, dull, burning, sharp needle, migraine line pains, sinus pressure, head pressure, tinnitus, heightened anxiety, nerve zaps in brain, toes and tooth, dizziness, brain fog, speech problem, mini stroke like symptoms, insomnia, base skull feels swollen. ER, primary doc, neurons and physical therapists being seen. No treatments avail...VAX reaction confirmed. High inflammation markers. Adverse event start date reported as 06May2021 08:00 am. Events resulted in Doctor or other healthcare professional office/clinic visit, Emergency room/department or urgent care, Life threatening illness (immediate risk of death from the event), Disability or permanent damage. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient has been tested for COVID-19. Covid test post vaccination covid test type post vaccination: Nasal Swab on 11Jul2021: Negative. Treatment was unknown. The patient was not recovered.
Age: 41.0
Sex: F
Vaccine: COVID19, COVID19, COVID19, COVID19
Symptoms: Anaphylactic reaction, Anxiety, Burning sensation, Dizziness, Electric shock sensation
Clinical narrative: Mild anaphylactic throat swelling at clinic; Mild anaphylactic throat swelling at clinic; left side head nerve inflammation; ear muffled- no infection; head twitching/spasm, dull, burning, sharp, neddle; head twitching/spasm, dull, burning, sharp, neddle; head twitching/spasm, dull, burning, sharp, neddle/head pressure; head twitching/spasm, dull, burning, sharp, neddle/head pressure; head twitching/spasm, dull, burning, sharp, neddle; migraine line pains; sinus pressure; tinnitus; heightened anxiety; nerve zaps in brain, toes and tooth; dizziness; bdain fog; speech problem; mini stroke like symptoms; insomnia; base skull feels swollen; High inflammation markers; This is a spontaneous report from a contactable consumer (patient). This 41-year-old female patient received bnt162b2 (Brand: Pfizer), dose 2 via an unspecified route of administration, administered in arm right on 23Mar2021 (Batch/Lot Number: ER781) as dose 2, single at the age of 41-year-old for covid-19 immunisation. Medical history included high bp and known allergies penicillin. Concomitant medications included hydroxyzine hydrochloride (HYDROXIZINE) taken for an unspecified indication, start and stop date were not reported; hydrochlorothiazide, losartan potassium (LOSARTAN HCTZ) taken for an unspecified indication, start and stop date were not reported. No other vaccine in four weeks. Facility where the most recent COVID-19 vaccine was administered: Other. First dose was received on 23Mar2021 08:30 am in arm left at the age of 41-year-old with Batch/lot number: EN6208 and experienced all Left side - Face numbness, mild inner mouth swelling, ER visit, went away after 2 weeks, and very heavy legs. Adverse event 2nd dose: mild anaphylactic throat swelling at clinic, doubled on hydroxyzine per nurse. 10 days post (as reported): left side head nerve inflammation, ear muffled- no infection, head twitching/spasm, dull, burning, sharp needle, migraine line pains, sinus pressure, head pressure, tinnitus, heightened anxiety, nerve zaps in brain, toes and tooth, dizziness, brain fog, speech problem, mini stroke like symptoms, insomnia, base skull feels swollen. ER, primary doc, neurons and physical therapists being seen. No treatments avail...VAX reaction confirmed. High inflammation markers. Adverse event start date reported as 06May2021 08:00 am. Events resulted in Doctor or other healthcare professional office/clinic visit, Emergency room/department or urgent care, Life threatening illness (immediate risk of death from the event), Disability or permanent damage. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient has been tested for COVID-19. Covid test post vaccination covid test type post vaccination: Nasal Swab on 11Jul2021: Negative. Treatment was unknown. The patient was not recovered.
Age: 41.0
Sex: F
Vaccine: COVID19, COVID19, COVID19, COVID19
Symptoms: Feeling abnormal, Head discomfort, Headache, Hypoacusis, Inflammation
Clinical narrative: Mild anaphylactic throat swelling at clinic; Mild anaphylactic throat swelling at clinic; left side head nerve inflammation; ear muffled- no infection; head twitching/spasm, dull, burning, sharp, neddle; head twitching/spasm, dull, burning, sharp, neddle; head twitching/spasm, dull, burning, sharp, neddle/head pressure; head twitching/spasm, dull, burning, sharp, neddle/head pressure; head twitching/spasm, dull, burning, sharp, neddle; migraine line pains; sinus pressure; tinnitus; heightened anxiety; nerve zaps in brain, toes and tooth; dizziness; bdain fog; speech problem; mini stroke like symptoms; insomnia; base skull feels swollen; High inflammation markers; This is a spontaneous report from a contactable consumer (patient). This 41-year-old female patient received bnt162b2 (Brand: Pfizer), dose 2 via an unspecified route of administration, administered in arm right on 23Mar2021 (Batch/Lot Number: ER781) as dose 2, single at the age of 41-year-old for covid-19 immunisation. Medical history included high bp and known allergies penicillin. Concomitant medications included hydroxyzine hydrochloride (HYDROXIZINE) taken for an unspecified indication, start and stop date were not reported; hydrochlorothiazide, losartan potassium (LOSARTAN HCTZ) taken for an unspecified indication, start and stop date were not reported. No other vaccine in four weeks. Facility where the most recent COVID-19 vaccine was administered: Other. First dose was received on 23Mar2021 08:30 am in arm left at the age of 41-year-old with Batch/lot number: EN6208 and experienced all Left side - Face numbness, mild inner mouth swelling, ER visit, went away after 2 weeks, and very heavy legs. Adverse event 2nd dose: mild anaphylactic throat swelling at clinic, doubled on hydroxyzine per nurse. 10 days post (as reported): left side head nerve inflammation, ear muffled- no infection, head twitching/spasm, dull, burning, sharp needle, migraine line pains, sinus pressure, head pressure, tinnitus, heightened anxiety, nerve zaps in brain, toes and tooth, dizziness, brain fog, speech problem, mini stroke like symptoms, insomnia, base skull feels swollen. ER, primary doc, neurons and physical therapists being seen. No treatments avail...VAX reaction confirmed. High inflammation markers. Adverse event start date reported as 06May2021 08:00 am. Events resulted in Doctor or other healthcare professional office/clinic visit, Emergency room/department or urgent care, Life threatening illness (immediate risk of death from the event), Disability or permanent damage. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient has been tested for COVID-19. Covid test post vaccination covid test type post vaccination: Nasal Swab on 11Jul2021: Negative. Treatment was unknown. The patient was not recovered.
Age: 41.0
Sex: F
Vaccine: COVID19, COVID19, COVID19, COVID19
Symptoms: Inflammatory marker test, Insomnia, Migraine, Muscle spasms, Muscle twitching
Clinical narrative: Mild anaphylactic throat swelling at clinic; Mild anaphylactic throat swelling at clinic; left side head nerve inflammation; ear muffled- no infection; head twitching/spasm, dull, burning, sharp, neddle; head twitching/spasm, dull, burning, sharp, neddle; head twitching/spasm, dull, burning, sharp, neddle/head pressure; head twitching/spasm, dull, burning, sharp, neddle/head pressure; head twitching/spasm, dull, burning, sharp, neddle; migraine line pains; sinus pressure; tinnitus; heightened anxiety; nerve zaps in brain, toes and tooth; dizziness; bdain fog; speech problem; mini stroke like symptoms; insomnia; base skull feels swollen; High inflammation markers; This is a spontaneous report from a contactable consumer (patient). This 41-year-old female patient received bnt162b2 (Brand: Pfizer), dose 2 via an unspecified route of administration, administered in arm right on 23Mar2021 (Batch/Lot Number: ER781) as dose 2, single at the age of 41-year-old for covid-19 immunisation. Medical history included high bp and known allergies penicillin. Concomitant medications included hydroxyzine hydrochloride (HYDROXIZINE) taken for an unspecified indication, start and stop date were not reported; hydrochlorothiazide, losartan potassium (LOSARTAN HCTZ) taken for an unspecified indication, start and stop date were not reported. No other vaccine in four weeks. Facility where the most recent COVID-19 vaccine was administered: Other. First dose was received on 23Mar2021 08:30 am in arm left at the age of 41-year-old with Batch/lot number: EN6208 and experienced all Left side - Face numbness, mild inner mouth swelling, ER visit, went away after 2 weeks, and very heavy legs. Adverse event 2nd dose: mild anaphylactic throat swelling at clinic, doubled on hydroxyzine per nurse. 10 days post (as reported): left side head nerve inflammation, ear muffled- no infection, head twitching/spasm, dull, burning, sharp needle, migraine line pains, sinus pressure, head pressure, tinnitus, heightened anxiety, nerve zaps in brain, toes and tooth, dizziness, brain fog, speech problem, mini stroke like symptoms, insomnia, base skull feels swollen. ER, primary doc, neurons and physical therapists being seen. No treatments avail...VAX reaction confirmed. High inflammation markers. Adverse event start date reported as 06May2021 08:00 am. Events resulted in Doctor or other healthcare professional office/clinic visit, Emergency room/department or urgent care, Life threatening illness (immediate risk of death from the event), Disability or permanent damage. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient has been tested for COVID-19. Covid test post vaccination covid test type post vaccination: Nasal Swab on 11Jul2021: Negative. Treatment was unknown. The patient was not recovered.
Age: 41.0
Sex: F
Vaccine: COVID19, COVID19, COVID19, COVID19
Symptoms: Neuritis, Paranasal sinus discomfort, Pharyngeal swelling, SARS-CoV-2 test, Speech disorder
Clinical narrative: Mild anaphylactic throat swelling at clinic; Mild anaphylactic throat swelling at clinic; left side head nerve inflammation; ear muffled- no infection; head twitching/spasm, dull, burning, sharp, neddle; head twitching/spasm, dull, burning, sharp, neddle; head twitching/spasm, dull, burning, sharp, neddle/head pressure; head twitching/spasm, dull, burning, sharp, neddle/head pressure; head twitching/spasm, dull, burning, sharp, neddle; migraine line pains; sinus pressure; tinnitus; heightened anxiety; nerve zaps in brain, toes and tooth; dizziness; bdain fog; speech problem; mini stroke like symptoms; insomnia; base skull feels swollen; High inflammation markers; This is a spontaneous report from a contactable consumer (patient). This 41-year-old female patient received bnt162b2 (Brand: Pfizer), dose 2 via an unspecified route of administration, administered in arm right on 23Mar2021 (Batch/Lot Number: ER781) as dose 2, single at the age of 41-year-old for covid-19 immunisation. Medical history included high bp and known allergies penicillin. Concomitant medications included hydroxyzine hydrochloride (HYDROXIZINE) taken for an unspecified indication, start and stop date were not reported; hydrochlorothiazide, losartan potassium (LOSARTAN HCTZ) taken for an unspecified indication, start and stop date were not reported. No other vaccine in four weeks. Facility where the most recent COVID-19 vaccine was administered: Other. First dose was received on 23Mar2021 08:30 am in arm left at the age of 41-year-old with Batch/lot number: EN6208 and experienced all Left side - Face numbness, mild inner mouth swelling, ER visit, went away after 2 weeks, and very heavy legs. Adverse event 2nd dose: mild anaphylactic throat swelling at clinic, doubled on hydroxyzine per nurse. 10 days post (as reported): left side head nerve inflammation, ear muffled- no infection, head twitching/spasm, dull, burning, sharp needle, migraine line pains, sinus pressure, head pressure, tinnitus, heightened anxiety, nerve zaps in brain, toes and tooth, dizziness, brain fog, speech problem, mini stroke like symptoms, insomnia, base skull feels swollen. ER, primary doc, neurons and physical therapists being seen. No treatments avail...VAX reaction confirmed. High inflammation markers. Adverse event start date reported as 06May2021 08:00 am. Events resulted in Doctor or other healthcare professional office/clinic visit, Emergency room/department or urgent care, Life threatening illness (immediate risk of death from the event), Disability or permanent damage. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient has been tested for COVID-19. Covid test post vaccination covid test type post vaccination: Nasal Swab on 11Jul2021: Negative. Treatment was unknown. The patient was not recovered.
Age: 41.0
Sex: F
Vaccine: COVID19, COVID19, COVID19, COVID19
Symptoms: Swelling, Tinnitus, Transient ischaemic attack
Clinical narrative: Mild anaphylactic throat swelling at clinic; Mild anaphylactic throat swelling at clinic; left side head nerve inflammation; ear muffled- no infection; head twitching/spasm, dull, burning, sharp, neddle; head twitching/spasm, dull, burning, sharp, neddle; head twitching/spasm, dull, burning, sharp, neddle/head pressure; head twitching/spasm, dull, burning, sharp, neddle/head pressure; head twitching/spasm, dull, burning, sharp, neddle; migraine line pains; sinus pressure; tinnitus; heightened anxiety; nerve zaps in brain, toes and tooth; dizziness; bdain fog; speech problem; mini stroke like symptoms; insomnia; base skull feels swollen; High inflammation markers; This is a spontaneous report from a contactable consumer (patient). This 41-year-old female patient received bnt162b2 (Brand: Pfizer), dose 2 via an unspecified route of administration, administered in arm right on 23Mar2021 (Batch/Lot Number: ER781) as dose 2, single at the age of 41-year-old for covid-19 immunisation. Medical history included high bp and known allergies penicillin. Concomitant medications included hydroxyzine hydrochloride (HYDROXIZINE) taken for an unspecified indication, start and stop date were not reported; hydrochlorothiazide, losartan potassium (LOSARTAN HCTZ) taken for an unspecified indication, start and stop date were not reported. No other vaccine in four weeks. Facility where the most recent COVID-19 vaccine was administered: Other. First dose was received on 23Mar2021 08:30 am in arm left at the age of 41-year-old with Batch/lot number: EN6208 and experienced all Left side - Face numbness, mild inner mouth swelling, ER visit, went away after 2 weeks, and very heavy legs. Adverse event 2nd dose: mild anaphylactic throat swelling at clinic, doubled on hydroxyzine per nurse. 10 days post (as reported): left side head nerve inflammation, ear muffled- no infection, head twitching/spasm, dull, burning, sharp needle, migraine line pains, sinus pressure, head pressure, tinnitus, heightened anxiety, nerve zaps in brain, toes and tooth, dizziness, brain fog, speech problem, mini stroke like symptoms, insomnia, base skull feels swollen. ER, primary doc, neurons and physical therapists being seen. No treatments avail...VAX reaction confirmed. High inflammation markers. Adverse event start date reported as 06May2021 08:00 am. Events resulted in Doctor or other healthcare professional office/clinic visit, Emergency room/department or urgent care, Life threatening illness (immediate risk of death from the event), Disability or permanent damage. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient has been tested for COVID-19. Covid test post vaccination covid test type post vaccination: Nasal Swab on 11Jul2021: Negative. Treatment was unknown. The patient was not recovered.
Age: 60.0
Sex: M
Vaccine: COVID19, COVID19, COVID19, COVID19
Symptoms: Tinnitus
Clinical narrative: Six weeks later the patient woke up with ringing in both ears. The ringing is very loud and it is hard to hear anything else.  Patient stated that he has seen 2 different specialists. Each Dr. can not explain what's going on. Patient stated then when he contacts PHhizer they hang up on hom when he mentions ringing in his ears.
Age: 60.0
Sex: M
Vaccine: COVID19, COVID19, COVID19, COVID19
Symptoms: Computerised tomogram, Hypoacusis, Tinnitus
Clinical narrative: Six weeks later the patient woke up with ringing in both ears. The ringing is very loud and it is hard to hear anything else.  Patient stated that he has seen 2 different specialists. Each Dr. can not explain what's going on. Patient stated then when he contacts PHhizer they hang up on hom when he mentions ringing in his ears.
Age: 60.0
Sex: M
Vaccine: COVID19, COVID19, COVID19, COVID19
Symptoms: Acoustic stimulation tests, Computerised tomogram, Deafness, Insomnia, Nerve injury
Clinical narrative: Six weeks later the patient woke up with ringing in both ears. The ringing is very loud and it is hard to hear anything else.  Patient stated that he has seen 2 different specialists. Each Dr. can not explain what's going on. Patient stated then when he contacts PHhizer they hang up on hom when he mentions ringing in his ears.
Age: 60.0
Sex: M
Vaccine: COVID19, COVID19, COVID19, COVID19
Symptoms: Pain in extremity, Tinnitus
Clinical narrative: Six weeks later the patient woke up with ringing in both ears. The ringing is very loud and it is hard to hear anything else.  Patient stated that he has seen 2 different specialists. Each Dr. can not explain what's going on. Patient stated then when he contacts PHhizer they hang up on hom when he mentions ringing in his ears.
Age: 33.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Lip swelling, Pruritus, Swelling face, Urticaria
Clinical narrative: Patient reporting or observed to have: Skin and mucosal symptoms: hives, pruritus and facial swelling swelling of the lips Respiratory symptoms: none Cardiovascular symptoms: none Gastrointestinal symptoms: none Loss of consciousness: No  Patient denied shortness of breath, swelling of the throat.   Interventions:  Assessed patient, Emergency medications administered, Activated emergency response  and Given water/juice  1435 Patient given 50 mg of elixir benadryl.  1450 given 300 mcg epi IM Right deltoid, administered by EMS. Drawn up by onsite pharmacist.    Patient discharged with EMS taken to hospital.
Age: 30.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Bell's palsy, Computerised tomogram head, Ear pain, Facial paralysis, Hypoaesthesia
Clinical narrative: Ringing started in right ear 2 weeks after 2nd shot. Three weeks after 2nd shot I go Bells Palsy (never had before) that lasted 3 weeks. It went away but ringing in the right ear continues to this day and migraines got more frequent.
Age: 30.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Laboratory test
Clinical narrative: Ringing started in right ear 2 weeks after 2nd shot. Three weeks after 2nd shot I go Bells Palsy (never had before) that lasted 3 weeks. It went away but ringing in the right ear continues to this day and migraines got more frequent.
Age: 30.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Bell's palsy, Migraine, Tinnitus
Clinical narrative: Ringing started in right ear 2 weeks after 2nd shot. Three weeks after 2nd shot I go Bells Palsy (never had before) that lasted 3 weeks. It went away but ringing in the right ear continues to this day and migraines got more frequent.
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Deep vein thrombosis, Discomfort, Full blood count normal, Metabolic function test, Peripheral swelling
Clinical narrative: My son received a first dose of Pfzer vaccine and developed a blood clot.; This is a spontaneous report from a contactable consumer. The patient participated in patient assistance. This consumer (patient's parent) reported for a male patient (reporter's son) of an unspecified age received bnt162b2 (Pfizer-BioNTech COVID-19 Vaccine, Solution for injection,Batch/Lot number was not reported) via an unspecified route of administration on an unspecified date as DOSE 1, Single for covid-19 immunisation. The patient medical history and concomitant medications were not reported. The patient received a first dose of Pfzer vaccine and developed a blood clot on an unspecified date .Event was considered to be medically significant. The patient underwent lab test included ct scan, ultrasounds and hematology report. Based on the findings, it was concluding that since there was no anatomical or genetic issue, blood clot was caused by vaccine and the clinical outcome of event was unknown.  The lot number for the vaccine, [BNT162B2], was not provided and will be requested during follow up.
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Computerised tomogram, Haematology test, Thrombosis, Ultrasound scan
Clinical narrative: My son received a first dose of Pfzer vaccine and developed a blood clot.; This is a spontaneous report from a contactable consumer. The patient participated in patient assistance. This consumer (patient's parent) reported for a male patient (reporter's son) of an unspecified age received bnt162b2 (Pfizer-BioNTech COVID-19 Vaccine, Solution for injection,Batch/Lot number was not reported) via an unspecified route of administration on an unspecified date as DOSE 1, Single for covid-19 immunisation. The patient medical history and concomitant medications were not reported. The patient received a first dose of Pfzer vaccine and developed a blood clot on an unspecified date .Event was considered to be medically significant. The patient underwent lab test included ct scan, ultrasounds and hematology report. Based on the findings, it was concluding that since there was no anatomical or genetic issue, blood clot was caused by vaccine and the clinical outcome of event was unknown.  The lot number for the vaccine, [BNT162B2], was not provided and will be requested during follow up.
Age: 15.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Angiopathy, Autoimmune disorder, Rash
Clinical narrative: Rash developed and is now being followed for HSP from rheumatology. They?re saying the cause of this was the Covid vaccine and insist she not get another.
Age: 15.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Rash
Clinical narrative: Rash developed and is now being followed for HSP from rheumatology. They?re saying the cause of this was the Covid vaccine and insist she not get another.
Age: 58.0
Sex: F
Vaccine: COVID19, COVID19, COVID19, COVID19
Symptoms: COVID-19, Death, SARS-CoV-2 test positive
Clinical narrative: covid infection
Age: 58.0
Sex: F
Vaccine: COVID19, COVID19, COVID19, COVID19
Symptoms: COVID-19
Clinical narrative: covid infection
Age: 44.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Angiogram, Congestive cardiomyopathy, Dilatation ventricular, Dyspnoea, Electrocardiogram ambulatory abnormal
Clinical narrative: Orthopnea; chest tightness; heart palpitations (PVCs); Subsequently diagnosed as myocarditis; Dilated Cardiomyopathy; Heart symptoms began w/in 24 hours after second dose; Shortness of breath; Fatigue/exhaustion; Fluid retention; This is a spontaneous report from a contactable consumer (patient). A 44-year-old female patient received the second dose for BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE), via an unspecified route of administration, administered in left arm on 20Mar2021 10:00 (Batch/Lot Number: ER2613) (at the age of 44 years old) as single dose for covid-19 immunisation. Medical history included asthma, endometriosis, and food sensitivity to eggs and wheat. The patient was not pregnant at the time of vaccination. The first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE) was administered on 27Feb2021 at 10:15am via an unspecified route of administration, administered in left arm (lot number: EN6205) (at the age of 44 years old) as single dose for covid-19 immunisation and resulted in ER visit due to concerns of bowel obstruction, nausea, vomiting, severe pain/cramps, and constipation. Concomitant medication included montelukast sodium (SINGULAIR) taken for unknown indication, start and stop date were not reported; and a birth control pill. The patient experienced myocarditis, dilated cardiomyopathy, heart symptoms, shortness of breath, fatigue/exhaustion, fluid retention, all in Mar2021; orthopnea, chest tightness, heart palpitations (PVCs) on 21Mar2021. The clinical course was reported as follows: heart symptoms began w/in 24 hours after the second dose.  Orthopnea and chest tightness and heart palpitations (PVCs) since 21Mar2021. Patient had shortness of breath, fatigue, exhaustion, and fluid retention. Subsequently diagnosed as myocarditis. Dilated cardiomyopathy. Heart symptoms were worsening each month since Mar2021. The events resulted in doctor or other healthcare professional office/clinic visit and emergency room/department or urgent care. Treatment given for the events: beta blocker. Due to the events, the patient was hospitalized for 5 days. The patient was tested for Covid-19 post vaccination via nasal swab on the following dates: 03Mar2021, 11Mar2021, 13Mar2021, Mar2021, 02Apr2021, 05Apr2021, 21Apr2021, 24Apr2021, Jul2021, Jul2021, all negative. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient has not been tested positive for COVID-19. Outcome of the events was not recovered.
Age: 44.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Left atrial enlargement, Left ventricular dilatation, Magnetic resonance imaging abnormal, Myositis, Palpitations
Clinical narrative: Orthopnea; chest tightness; heart palpitations (PVCs); Subsequently diagnosed as myocarditis; Dilated Cardiomyopathy; Heart symptoms began w/in 24 hours after second dose; Shortness of breath; Fatigue/exhaustion; Fluid retention; This is a spontaneous report from a contactable consumer (patient). A 44-year-old female patient received the second dose for BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE), via an unspecified route of administration, administered in left arm on 20Mar2021 10:00 (Batch/Lot Number: ER2613) (at the age of 44 years old) as single dose for covid-19 immunisation. Medical history included asthma, endometriosis, and food sensitivity to eggs and wheat. The patient was not pregnant at the time of vaccination. The first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE) was administered on 27Feb2021 at 10:15am via an unspecified route of administration, administered in left arm (lot number: EN6205) (at the age of 44 years old) as single dose for covid-19 immunisation and resulted in ER visit due to concerns of bowel obstruction, nausea, vomiting, severe pain/cramps, and constipation. Concomitant medication included montelukast sodium (SINGULAIR) taken for unknown indication, start and stop date were not reported; and a birth control pill. The patient experienced myocarditis, dilated cardiomyopathy, heart symptoms, shortness of breath, fatigue/exhaustion, fluid retention, all in Mar2021; orthopnea, chest tightness, heart palpitations (PVCs) on 21Mar2021. The clinical course was reported as follows: heart symptoms began w/in 24 hours after the second dose.  Orthopnea and chest tightness and heart palpitations (PVCs) since 21Mar2021. Patient had shortness of breath, fatigue, exhaustion, and fluid retention. Subsequently diagnosed as myocarditis. Dilated cardiomyopathy. Heart symptoms were worsening each month since Mar2021. The events resulted in doctor or other healthcare professional office/clinic visit and emergency room/department or urgent care. Treatment given for the events: beta blocker. Due to the events, the patient was hospitalized for 5 days. The patient was tested for Covid-19 post vaccination via nasal swab on the following dates: 03Mar2021, 11Mar2021, 13Mar2021, Mar2021, 02Apr2021, 05Apr2021, 21Apr2021, 24Apr2021, Jul2021, Jul2021, all negative. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient has not been tested positive for COVID-19. Outcome of the events was not recovered.
Age: 44.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Pulmonary artery dilatation, Right atrial enlargement, Right ventricular enlargement, Ventricular extrasystoles
Clinical narrative: Orthopnea; chest tightness; heart palpitations (PVCs); Subsequently diagnosed as myocarditis; Dilated Cardiomyopathy; Heart symptoms began w/in 24 hours after second dose; Shortness of breath; Fatigue/exhaustion; Fluid retention; This is a spontaneous report from a contactable consumer (patient). A 44-year-old female patient received the second dose for BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE), via an unspecified route of administration, administered in left arm on 20Mar2021 10:00 (Batch/Lot Number: ER2613) (at the age of 44 years old) as single dose for covid-19 immunisation. Medical history included asthma, endometriosis, and food sensitivity to eggs and wheat. The patient was not pregnant at the time of vaccination. The first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE) was administered on 27Feb2021 at 10:15am via an unspecified route of administration, administered in left arm (lot number: EN6205) (at the age of 44 years old) as single dose for covid-19 immunisation and resulted in ER visit due to concerns of bowel obstruction, nausea, vomiting, severe pain/cramps, and constipation. Concomitant medication included montelukast sodium (SINGULAIR) taken for unknown indication, start and stop date were not reported; and a birth control pill. The patient experienced myocarditis, dilated cardiomyopathy, heart symptoms, shortness of breath, fatigue/exhaustion, fluid retention, all in Mar2021; orthopnea, chest tightness, heart palpitations (PVCs) on 21Mar2021. The clinical course was reported as follows: heart symptoms began w/in 24 hours after the second dose.  Orthopnea and chest tightness and heart palpitations (PVCs) since 21Mar2021. Patient had shortness of breath, fatigue, exhaustion, and fluid retention. Subsequently diagnosed as myocarditis. Dilated cardiomyopathy. Heart symptoms were worsening each month since Mar2021. The events resulted in doctor or other healthcare professional office/clinic visit and emergency room/department or urgent care. Treatment given for the events: beta blocker. Due to the events, the patient was hospitalized for 5 days. The patient was tested for Covid-19 post vaccination via nasal swab on the following dates: 03Mar2021, 11Mar2021, 13Mar2021, Mar2021, 02Apr2021, 05Apr2021, 21Apr2021, 24Apr2021, Jul2021, Jul2021, all negative. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient has not been tested positive for COVID-19. Outcome of the events was not recovered.
Age: 44.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Cardiac disorder, Chest discomfort, Congestive cardiomyopathy, Dyspnoea, Fatigue
Clinical narrative: Orthopnea; chest tightness; heart palpitations (PVCs); Subsequently diagnosed as myocarditis; Dilated Cardiomyopathy; Heart symptoms began w/in 24 hours after second dose; Shortness of breath; Fatigue/exhaustion; Fluid retention; This is a spontaneous report from a contactable consumer (patient). A 44-year-old female patient received the second dose for BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE), via an unspecified route of administration, administered in left arm on 20Mar2021 10:00 (Batch/Lot Number: ER2613) (at the age of 44 years old) as single dose for covid-19 immunisation. Medical history included asthma, endometriosis, and food sensitivity to eggs and wheat. The patient was not pregnant at the time of vaccination. The first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE) was administered on 27Feb2021 at 10:15am via an unspecified route of administration, administered in left arm (lot number: EN6205) (at the age of 44 years old) as single dose for covid-19 immunisation and resulted in ER visit due to concerns of bowel obstruction, nausea, vomiting, severe pain/cramps, and constipation. Concomitant medication included montelukast sodium (SINGULAIR) taken for unknown indication, start and stop date were not reported; and a birth control pill. The patient experienced myocarditis, dilated cardiomyopathy, heart symptoms, shortness of breath, fatigue/exhaustion, fluid retention, all in Mar2021; orthopnea, chest tightness, heart palpitations (PVCs) on 21Mar2021. The clinical course was reported as follows: heart symptoms began w/in 24 hours after the second dose.  Orthopnea and chest tightness and heart palpitations (PVCs) since 21Mar2021. Patient had shortness of breath, fatigue, exhaustion, and fluid retention. Subsequently diagnosed as myocarditis. Dilated cardiomyopathy. Heart symptoms were worsening each month since Mar2021. The events resulted in doctor or other healthcare professional office/clinic visit and emergency room/department or urgent care. Treatment given for the events: beta blocker. Due to the events, the patient was hospitalized for 5 days. The patient was tested for Covid-19 post vaccination via nasal swab on the following dates: 03Mar2021, 11Mar2021, 13Mar2021, Mar2021, 02Apr2021, 05Apr2021, 21Apr2021, 24Apr2021, Jul2021, Jul2021, all negative. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient has not been tested positive for COVID-19. Outcome of the events was not recovered.
Age: 44.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Fluid retention, Myocarditis, Orthopnoea, Palpitations, SARS-CoV-2 test
Clinical narrative: Orthopnea; chest tightness; heart palpitations (PVCs); Subsequently diagnosed as myocarditis; Dilated Cardiomyopathy; Heart symptoms began w/in 24 hours after second dose; Shortness of breath; Fatigue/exhaustion; Fluid retention; This is a spontaneous report from a contactable consumer (patient). A 44-year-old female patient received the second dose for BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE), via an unspecified route of administration, administered in left arm on 20Mar2021 10:00 (Batch/Lot Number: ER2613) (at the age of 44 years old) as single dose for covid-19 immunisation. Medical history included asthma, endometriosis, and food sensitivity to eggs and wheat. The patient was not pregnant at the time of vaccination. The first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE) was administered on 27Feb2021 at 10:15am via an unspecified route of administration, administered in left arm (lot number: EN6205) (at the age of 44 years old) as single dose for covid-19 immunisation and resulted in ER visit due to concerns of bowel obstruction, nausea, vomiting, severe pain/cramps, and constipation. Concomitant medication included montelukast sodium (SINGULAIR) taken for unknown indication, start and stop date were not reported; and a birth control pill. The patient experienced myocarditis, dilated cardiomyopathy, heart symptoms, shortness of breath, fatigue/exhaustion, fluid retention, all in Mar2021; orthopnea, chest tightness, heart palpitations (PVCs) on 21Mar2021. The clinical course was reported as follows: heart symptoms began w/in 24 hours after the second dose.  Orthopnea and chest tightness and heart palpitations (PVCs) since 21Mar2021. Patient had shortness of breath, fatigue, exhaustion, and fluid retention. Subsequently diagnosed as myocarditis. Dilated cardiomyopathy. Heart symptoms were worsening each month since Mar2021. The events resulted in doctor or other healthcare professional office/clinic visit and emergency room/department or urgent care. Treatment given for the events: beta blocker. Due to the events, the patient was hospitalized for 5 days. The patient was tested for Covid-19 post vaccination via nasal swab on the following dates: 03Mar2021, 11Mar2021, 13Mar2021, Mar2021, 02Apr2021, 05Apr2021, 21Apr2021, 24Apr2021, Jul2021, Jul2021, all negative. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient has not been tested positive for COVID-19. Outcome of the events was not recovered.
Age: 18.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Blood test, Colonoscopy, Computerised tomogram abdomen, Computerised tomogram pelvis, Constipation
Clinical narrative: intermittent vomiting; lack of energy; inertia; bedridden; constipation; This is a spontaneous report from a contactable physician.   A 18-year-old (non-pregnant) female patient received first dose of bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE; Solution for injection, Batch/Lot Number: unknown), via an unspecified route of administration, administered on 15Apr2021 as SINGLE dose and patient administered second dose of bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE; Solution for injection, Batch/Lot Number: unknown), via an unspecified route of administration, administered on unspecified date in May2021 as SINGLE dose for covid-19 immunisation. The patient medical history was not reported. The patient's concomitant medications were not reported. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. It was unknown patient did not receive other medications within 2 weeks of vaccination. The patient stated 4 days later she began to have intermittent vomiting, lack of energy, inertia on 19Apr2021. Over the next 8 weeks she went from being a healthy 18 year old who ran 6 miles a day to being bedridden on 19Apr2021. She has constipation on 19Apr2021 and requires bladder catheterization. She has been evaluated by multiple doctors including the (Withheld) and was to be evaluated yesterday at the (Withheld). She is too weak to travel by plane. The patient was hospitalized for intermittent vomiting, lack of energy, inertia and constipation for 8 days.  Prior to vaccination, the patient did not diagnosed with COVID-19. Since the vaccination, it was unknown if the patient tested for COVID-19. Therapeutic measures were taken as a result of intermittent vomiting, lack of energy, inertia, bedridden and constipation The patient underwent lab tests and procedures which included Cardiac ( investigation): unknown on unspecified date, Multiple MRIs (magnetic resonance imaging): unknown on unspecified date, Neurologic (neurological examination): unknown  on unspecified date, psychiatric evaluation (psychiatric evaluation): unknown on unspecified date, GI ( x-ray gastrointestinal tract): unknown on unspecified date. The outcome of all event was not recovered.  Information on lot/batch number has been requested.; Sender's Comments: Based on plausible temporal relationship, a possible causal association between the reported events and the suspect drug BNT162B2 cannot be excluded. The impact of this report on the benefit/risk profile of the Pfizer product is evaluated as part of Pfizer procedures for safety evaluation, including the review and analysis of aggregate data for adverse events. Any safety concern identified as part of this review, as well as any appropriate action in response, will be promptly notified to regulatory authorities, Ethics Committees, and Investigators, as appropriate.